These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32519166)

  • 21. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AF.
    Koretsune Y; Etoh T; Katsuda Y; Suetsugu T; Kumeda K; Sakuma I; Eshima K; Shibuya M; Ando SI; Yokota N; Goto S; Pieper KS; Allu J; Kakkar AK;
    Circ J; 2018 Dec; 83(1):67-74. PubMed ID: 30518731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database.
    Urbaniak AM; Strøm BO; Krontveit R; Svanqvist KH
    Drugs Aging; 2017 Aug; 34(8):635-645. PubMed ID: 28710707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
    Emren SV; Zoghi M; Berilgen R; Özdemir İH; Çelik O; Çetin N; Enhoş A; Köseoğlu C; Akyüz A; Doğan V; Levent F; Dereli Y; Doğan T; Başaran Ö; Karaca I; Karaca Ö; Otlu YÖ; Özmen Ç; Coşar S; Sümerkan M; Gürsul E; İnci S; Onrat E; Ergene O
    Bosn J Basic Med Sci; 2018 May; 18(2):185-190. PubMed ID: 28968197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
    Haas S; Camm AJ; Bassand JP; Angchaisuksiri P; Cools F; Corbalan R; Gibbs H; Jacobson B; Koretsune Y; Mantovani LG; Misselwitz F; Panchenko E; Ragy HI; Stepinska J; Turpie AG; Sawhney JP; Steffel J; Lim TW; Pieper KS; Virdone S; Verheugt FW; Kakkar AK;
    Am Heart J; 2019 Jul; 213():35-46. PubMed ID: 31128503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.
    Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
    Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
    BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry.
    Ono T; Ikemura N; Kimura T; Ueda I; Tanaka H; Tokuda H; Yajima N; Matsumura K; Suzuki M; Fukuda K; Kohsaka S; Takatsuki S
    J Cardiol; 2019 Jan; 73(1):14-21. PubMed ID: 30487057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
    Degli Esposti L; Perrone V; Saragoni S; Buda S; Piovaccari G
    G Ital Cardiol (Rome); 2020 Jan; 21(1):25-33. PubMed ID: 31960832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of anticoagulants in the management of atrial fibrillation among general practices in England.
    Cowan C; Healicon R; Robson I; Long WR; Barrett J; Fay M; Tyndall K; Gale CP
    Heart; 2013 Aug; 99(16):1166-72. PubMed ID: 23393083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.
    Mostaza JM; Suarez C; Cepeda JM; Manzano L; Sánchez D;
    BMC Cardiovasc Disord; 2021 Aug; 21(1):384. PubMed ID: 34372782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain.
    Polo García J; Vargas Ortega D; Formiga F; Unzueta I; Fernández de Cabo S; Chaves J
    Semergen; 2019 Sep; 45(6):396-405. PubMed ID: 30573367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.